Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of IDH1 Inhibition With Ivosidenib as Maintenance Therapy After Ivosidenib, Azacitidine, and Venetoclax for Acute Myeloid Leukemia

NCT07392242 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT07392242
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07392242 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of IDH1 Inhibition With Ivosidenib as Maintenance Therapy After Ivosidenib, Azacitidine, and Venetoclax for Acute Myeloid Leukemia
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 2
Overall status
Recruiting
Start date
January 27, 2026
Completion date
January 31, 2028
Enrollment
45 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia